市場調査レポート

世界のペプチドワクチン市場とパイプライン分析

Global Peptide Vaccine Market & Pipeline Insight

発行 KuicK Research 商品コード 322278
出版日 ページ情報 英文 200 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.16円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界のペプチドワクチン市場とパイプライン分析 Global Peptide Vaccine Market & Pipeline Insight
出版日: 2015年01月01日 ページ情報: 英文 200 Pages
概要

ペプチドワクチンは、ペプチド自体で薬理活性を示すのではなく、ヒト免疫系を活性化させることによって、薬理学的特性を示します。ペプチドワクチンの研究・開発は、この10年間、製薬業界でかなりの勢いを得てきました。高い安全性と有効性レベル、最小限の副作用が、ペプチドワクチンへの多額の投資に対する最重要要因になっています。

当レポートでは、世界のペプチドワクチン市場について調査分析し、市場の概要・機序、市場力学(促進要因、課題、将来の見通し)、パイプライン(相別、適応別、企業別、国別)、臨床パイプライン、上市製品などについて、体系的な情報を提供しています。

第1章 ペプチドワクチンの概要

第2章 ペプチドワクチンの機序

第3章 世界のペプチドワクチン市場の概要

  • 現在の市場シナリオ
  • ペプチドワクチン臨床パイプラインの概要

第4章 世界のペプチドワクチンの市場力学

  • 市場促進要因
  • 課題

第5章 世界のペプチドワクチン市場の将来見通し

第6章 世界のペプチドワクチンパイプライン:相別、適応別、企業別、国別

  • 研究
  • 前臨床
  • 臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相

第7章 ペプチドワクチン臨床パイプラインにおける開発の中断/中止報告

  • 開発報告なし
  • 中止

第8章 競合情勢

  • Apitope Technology
  • BiondVax Pharmaceuticals Ltd
  • Circassia
  • Eli Lily
  • Galena Biopharmaceuticals
  • GlaxoSmithKline
  • Hyperion Therapeutics
  • ImmunoCellular Therapeutics
  • Merck
  • OncoTherapy Science

図表

目次

Peptide vaccines are peptides that exhibit pharmacological properties by activating human immune system rather than showing pharmacologically activity by themselves. They are administered into body to enter in lymph nodes where they induce long lasting immune response. They utilize immune system and develop long term acquired immunity which has capability to prevent future incidences of pathogen attack. Every living cell in human body has surface markers as an instrument to identify self from non-self which is artificially provided by vaccines. When foreign entity penetrates into the body, defence mechanism already triggered by vaccines gets activated to protect from spread of pathogen.

Peptide vaccines also follow the same principles followed by conventional vaccines. It must contain a part of pathogen mimicking protein in their structure. This mimicking molecule enters the body and causes a series of reactions leading to the activation immune system. Body mistook it as an attack by pathogen while in reality it is harmless peptide vaccine. The immune system gets activated and prevents the potential attack done by pathogenic microorganism. The potential of therapeutic drugs in saving lives has been proved and investigators are increasing their focus on development of prophylactic peptide vaccines.

The research and development of peptide vaccines has gained significant momentum in pharmaceutical industry during past decade. The high safety and efficacy levels and minimum side effects is the most important factor for large investments in this segment. Different methods have been found by researchers that offers cost effectiveness to patients besides therapeutic benefits. Pharmaceuticals companies are trying to find innovative methods that could strengthen and diversify their portfolio.

Progress in recombinant DNA technology is the basis of development of peptide vaccine without which current progress has not been achieved by pharmaceutical companies. Market growth of peptide vaccine is dependent on this field and the amount of funds diverged to this segment. To generate more revenues funds invested will increase at significant rates for the development of innovative peptide vaccines. It is expected that the next-generation peptide vaccines presently under investigation would pass through regulatory hurdle, clinical trials and marketed in near future.

Various peptide vaccines available in market have been made by using different methods of recombinant DNA technology. Subunit vaccines group seems to occupy large market in coming years due to their versatile nature and ease of development. Large scale manufacturing if also easy with minimal number steps that helps in decreasing time, reduce wastage of raw materials and have high cost-arbitrage. Over time, reduced marketing time coupled with their therapeutic property will make them highly suitable candidate with optimistic growth potential.

Peptide vaccines for treatment and prevention of cancer are expected to occupy a major share in global vaccine market as well as in other fields like infectious and neurobiological disease. It is expected that investigators would be able to extend the indications for the peptide vaccines in near future that would be instrumental in widespread penetration of peptide vaccines. Immunotoxicity, clinical/ preclinical requirements and regulatory issues are realistic hurdles which may limit the market penetration of peptide vaccines at global level. Many peptide vaccines have successfully made niche in global market which gives an idea about optimistic future that would be achieved in coming years.

"Global Peptide Vaccine Market & Pipeline Insight" Report Highlights:

  • Introduction & Mechanism of Peptide Vaccine
  • Peptide Vaccine Market Overview
  • Peptide Vaccine Market Dynamics (Drivers, Challenges & Future Outlook)
  • Peptide Vaccine Pipeline by Phase, Indication, Company & Country
  • Peptide Vaccine Pipeline in Clinical Pipeline: 69
  • Majority of Peptide Vaccine in Preclinical Phase: 19
  • Competitive Landscape & Patent Analysis

Table of Contents

1. Introduction to Peptide Vaccine

2. Mechanism of Peptide Vaccine

3. Global Peptide Vaccine Market Overview

  • 3.1 Current Market Scenario
  • 3.2 Peptide Vaccine Clinical Pipeline Overview

4. Global Peptide Vaccine Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Challenges

5. Global Peptide Vaccine Market Future Prospects

6. Global Peptide Vaccine Pipeline by Phase, Indication, Company & Country

  • 6.1 Research
  • 6.2 Preclinical
  • 6.3 Clinical
  • 6.4 Phase-I
  • 6.5 Phase-I/II
  • 6.6 Phase-II
  • 6.7 Phase-II/III
  • 6.8 Phase-III

7. Discontinued & No Development Reported in Peptide Vaccine Clinical Pipeline

  • 7.1 No Development Reported
  • 7.2 Discontinued

8. Competitive Landscape

  • 8.1 Apitope Technology
  • 8.2 BiondVax Pharmaceuticals Ltd
  • 8.3 Circassia
  • 8.4 Eli Lily
  • 8.5 Galena Biopharmaceuticals
  • 8.6 GlaxoSmithKline
  • 8.7 Hyperion Therapeutics
  • 8.8 ImmunoCellular Therapeutics
  • 8.9 Merck
  • 8.10 OncoTherapy Science
  • Figure 1-1: Different Types of Vaccines
  • Figure 1-2: Criteria for Ideal Peptide Vaccine
  • Figure 1-3: Peptide Vaccines Delivery System
  • Figure 2-1: Mechanism of Peptide Vaccines
  • Figure 2-2: Mechanism of Live Vaccines
  • Figure 2-3: Mechanism of Toxoid & Inactivated Vaccine
  • Figure 2-4: Mode of Action of Peptide Cancer Vaccines
  • Figure 3-1: Global Peptide Vaccine Pipeline by Phase (%), 2014
  • Figure 3-2: Global Peptide Vaccine Pipeline by Phase (Number), 2014
  • Figure 3-3: No Development Reported in Global Peptide Vaccine Pipeline by Phase (%), 2014
  • Figure 3-4: No Development Reported in Global Peptide Vaccine Pipeline by Phase (Number), 2014
  • Figure 3-5: Discontinued Peptide Vaccine Pipeline by Phase (%), 2014
  • Figure 3-6: Discontinued Peptide Vaccine Pipeline by Phase (Number), 2014
  • Figure 4-1: Global Peptide Vaccine Market Drivers
  • Figure 4-2: Global Peptide Vaccine Market Challenges
Back to Top